UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Del ...

LISTHER ATAPEUTICS A Targeted Therapy Delivered David J. Mazzo, Ph.D. Chief Executive Officer LD Micro Main Event XV| October 2022 Nasdaq: LSTA www.lisata.com Copyright ©2022 Lisata Therapeutics, Inc. All rights reserved. Forward-looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, i ...

Caladrius Biosciences, Inc. (CLBS) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David Mazzo - President, CEO Kristen Buck - EVP, Research and Development & CMO James Nisco - VP, Finance & Treasury Conference Call Participants Kumar Raja - Brookline Capital Pete Enderlin - MAZ Partners Operator Welcome to the Caladrius Biosciences' Second Quarter 2022 Financial Results and Business Update Conference Call. Currently all partic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) | Dela ...

caladrius Developing Innovative Therapies that Treat or Reverse Disease David J. Mazzo, PhD President & Chief Executive Officer M ay 5 , 2 0 22| N a s d a q : C L B S 2 Information regarding disclosures Forward-Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this com ...

Call Start: 16:30 January 1, 0000 5:07 PM ET Caladrius Biosciences, Inc. (CLBS) Q1 2022 Earnings Conference Call May 5, 2022 16:30 ET Company Participants John Menditto - Vice President of Investor Relations & Corporate Communications David Mazzo - President & Chief Executive Officer James Nisco - Vice President of Finance & Treasury Kristen Buck - Chief Medical Officer Conference Call Participants Kumar Raja - Brookline Capital Markets Emanuela Branchetti - H.C. Wainwright Pete Enderlin - MAZ Partners Oper ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FOR THE QUARTERLY PERIOD ENDED March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) | Del ...

Caladrius Biosciences, Inc. (CLBS) Q4 2021 Earnings Conference Call March 22, 2022 4:30 PM ET Company Participants John Menditto – Vice President-Investor Relations and Corporate Communications David Mazzo – President and Chief Executive Officer James Nisco – Vice President-Finance and Treasury Kristen Buck – Executive Vice President-Research and Development and Chief Medical Officer Conference Call Participants Kumar Raja – Brookline Capital Markets Lander Ron – H.C. Wainwright Pete Enderlin – MAZ Partners ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FOR THE FISCAL YEAR ENDED December 31, 2021 OR Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 CALADRIUS BIOSCIENCES, INC. Delaware 22-2343568 (State or other jurisdiction of (I ...

Caladrius Biosciences, Inc. (CLBS) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants John Menditto - Vice President-Investor Relations and Corporate Communications David Mazzo - President and Chief Executive Officer Kristen Buck - Executive Vice President of R&D and Chief Medical Officer James Nisco - Vice President-Finance and Treasury Conference Call Participants Kumaraguru Raja - Brookline Capital Markets Emanuela Branchetti - H.C. Wainwright Peter Enderlin - MAZ Partners ...